TITLE

Ahead of OncoGenex Merger, Sonus Adds Caspase Program

AUTHOR(S)
Boggs, Jennifer
PUB. DATE
August 2008
SOURCE
BioWorld Today;8/8/2008, Vol. 19 Issue 154, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article deals with the decision of Sonus Pharmaceuticals Inc. to license an early caspase activator program from Bayer HealthCare LLC. The caspase activator program will become part of the upcoming merger of Sonus with OncoGenex Technologies Inc. The license obtained by Sonus enables it to develop a family of preclinical small-molecule compounds that can induce cell death through the activation of the caspase pathway. It is said that caspases are targeted by tumor cells because the cells have lost the ability to complete the cell death process.
ACCESSION #
33626255

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics